We are live on !
Find out more
March Altus Capital Management Portfolio holdings
AUM
$16M
Turnover
41.67%
1-Year Est. Return
18.92%
This Fund
S&P 500
This Quarter Est. Return
+15.65%
1 Year Est. Return
+18.92%
3 Year Est. Return
+155.68%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$16M
AUM Growth
+$3.05M
(+24%)
Cap. Flow
+$1.62M
Cap. Flow % of AUM
Cap. Flow %
10.11%
Top 10 Holdings %
Top 10 Hldgs %
98.74%
Holding
12
New
4
Increased
2
Reduced
3
Closed
1
Avg Time Held
0.9
years
Top 10 Avg Time Held
0.8
years
Top 20 Avg Time Held
0.9
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Edwards Lifesciences
EW
|
+$1.81M |
| 2 |
TSRO
TESARO, Inc.
TSRO
|
+$934K |
| 3 |
Zoetis
ZTS
|
+$805K |
| 4 |
Biogen
BIIB
|
+$770K |
| 5 |
DexCom
DXCM
|
+$223K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Align Technology
ALGN
|
+$1.4M |
| 2 |
Eli Lilly
LLY
|
+$1.08M |
| 3 |
Acadia Pharmaceuticals
ACAD
|
+$339K |
| 4 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$309K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Edwards Lifesciences
EW
$60.4B
| $4.17M | 26.11% |
103,833
+48,000
| +86% | +$1.81M |
2015 Q3
4 quarters
|
|
|
2
Acadia Pharmaceuticals
ACAD
$3.13B
| $2.31M | 14.47% |
72,723
-10,000
| -12% | -$339K |
2015 Q3
4 quarters
|
|
|
PETX
3
DELISTED
Aratana Therapeutics, Inc.
PETX
| $2.04M | 12.79% |
218,515
| – | – |
2015 Q3
4 quarters
|
|
4
Johnson & Johnson
JNJ
$679B
| $1.54M | 9.61% |
13,000
| – | – |
2016 Q2
1 quarter
|
|
|
5
DexCom
DXCM
$29.8B
| $1.24M | 7.79% |
56,800
+10,000
| +21% | +$223K |
2013 Q4
11 quarters
|
|
|
6
Eli Lilly
LLY
$1.28T
| $1.07M | 6.68% |
13,310
-13,500
| -50% | -$1.08M |
2013 Q4
11 quarters
|
|
|
TSRO
7
DELISTED
TESARO, Inc.
TSRO
| $1M | 6.27% |
+10,000
| New | +$934K |
2016 Q3
0 quarters
|
|
|
8
Zoetis
ZTS
$33.9B
| $827K | 5.17% |
+15,900
| New | +$805K |
2016 Q3
0 quarters
|
|
|
9
Biogen
BIIB
$37.1B
| $814K | 5.09% |
+2,600
| New | +$770K |
2016 Q3
0 quarters
|
|
|
ALXN
10
DELISTED
Alexion Pharmaceuticals
ALXN
| $760K | 4.75% |
6,199
-2,400
| -28% | -$309K |
2015 Q4
3 quarters
|
|
11
Regeneron Pharmaceuticals
REGN
$98.6B
| $201K | 1.26% |
+500
| New | +$201K |
2016 Q3
0 quarters
|
|
|
12
Align Technology
ALGN
$11.8B
| – | – |
-17,319
| Closed | -$1.4M | – |
|
Similar funds
PA
CAD
March Altus Capital Management's Q3 2016 Portfolio in Review
As of Q3 2016, March Altus Capital Management held 12 positions worth $16M, up 24% from $12.9M the previous quarter. Its ten largest holdings account for 99% of the portfolio.
March Altus Capital Management deployed $1.62M of net new capital in Q3 2016, opening 4 new positions and adding to 2 existing holdings. Its largest new stake was TESARO, Inc.: 10,000 shares worth $1M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.
On the sell side, the largest reduction was Eli Lilly, an estimated $1.08M trimmed.
- March Altus Capital Management's largest Q3 2016 buy was TESARO, Inc.: 10,000 shares worth $1M.
- March Altus Capital Management added most to Edwards Lifesciences in Q3 2016, an estimated $1.81M increase.
- March Altus Capital Management's biggest Q3 2016 reduction was Eli Lilly, cutting an estimated $1.08M.
- March Altus Capital Management fully exited Align Technology in Q3 2016, selling an estimated $1.4M.
- March Altus Capital Management's ten largest holdings make up 99% of its $16M portfolio in Q3 2016.
- March Altus Capital Management opened 4 new positions and closed 1 in Q3 2016.
- March Altus Capital Management's portfolio value rose 24% quarter-over-quarter to $16M.
Based on March Altus Capital Management's 13F filing for Q3 2016, filed 7 Nov 2016.